Miscellaneous

We believe we will be in the black, ... What I'm trying to do is a balancing act. The more read more

We believe we will be in the black, ... What I'm trying to do is a balancing act. The more money we make, the more we put in the field. That's the goal.

I don't want Doug Melvin with money burning a hole in his pocket, ... We're already scouting free agents for read more

I don't want Doug Melvin with money burning a hole in his pocket, ... We're already scouting free agents for next year. But we are not getting free agents if it's not the right fit.

It's been a priority for me that the fan experience be optimal, ... One of the things I've found traveling read more

It's been a priority for me that the fan experience be optimal, ... One of the things I've found traveling with the team to different cities is that we do give a good experience.

We believe that the Street does not fully appreciate the risks associated with the company's two lead programs.

We believe that the Street does not fully appreciate the risks associated with the company's two lead programs.

Vertex shares may not be for the faint-hearted at these price levels. However, the hepatitis C derby is just that: read more

Vertex shares may not be for the faint-hearted at these price levels. However, the hepatitis C derby is just that: a race. Should Vertex not stumble or encounter unforeseen obstacles prior to approval, $35 will wind up looking like an early exit point.

These results, like the 14-day study before it, are unprecedented, and offer strong support for a three-month course of therapy read more

These results, like the 14-day study before it, are unprecedented, and offer strong support for a three-month course of therapy as optimal duration.

Vertex shares are once again challenging our price target and with the stock up 250% over the past year, investors read more

Vertex shares are once again challenging our price target and with the stock up 250% over the past year, investors may be asking what to do with the stock. We would stick with Vertex.

We look for in-line fourth-quarter financial results and more upbeat guidance for 2006 than Amgen provided at this time last read more

We look for in-line fourth-quarter financial results and more upbeat guidance for 2006 than Amgen provided at this time last year for 2005.

The interim results are positive but may fall short of investor expectations.

The interim results are positive but may fall short of investor expectations.

We're still working on a number that would give us a high degree of confidence in our sample, but a read more

We're still working on a number that would give us a high degree of confidence in our sample, but a minimum would probably be 1,000 samples across the state.